AVKARE Inc. FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

  • Latest inspection VAI · Nov 2, 2022
  • 2 Class I recalls
  • No warning letters matched by name
Inspections 4 0 OAI
Recalls 62 2 Class I (3%)
Warning letters 0 None on file
510(k) clearances 0 None on file

AVKARE Inc. has 62 FDA recalls (2 Class I), 4 inspections, 0 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "AVKARE Inc." is on file.

What these totals cover: FDA records filed under the name "AVKARE Inc." and its spelling variants "Avkare", "Avkare Incorporated".

Latest recall
D-0341-2026 · Class II · Feb 13, 2026
Latest inspection
Nov 2, 2022 · VAI

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls62 (2 Class I)Nov 11, 2026 (checked Nov 15, 2026, unchanged)File dated Nov 10, 2026Current
510(k) clearances0Nov 15, 2026File dated Nov 9, 2026Current
Inspections4Nov 16, 2026Newest record Nov 5, 2026Current
Compliance actions0Nov 2, 2026Newest record Oct 29, 2026Current

FDA record by year

AVKARE Inc.'s FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

AVKARE Inc.: FDA inspections per year

2017: 1 inspection (0 OAI), 0 warning letters, 3 recall records (0 Class I) 2018: 0 inspections (0 OAI), 0 warning letters, 12 recall records (0 Class I) 2019: 0 inspections (0 OAI), 0 warning letters, 12 recall records (0 Class I) 2020: 0 inspections (0 OAI), 0 warning letters, 7 recall records (1 Class I) 2021: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2022: 2 inspections (0 OAI), 0 warning letters, 2 recall records (0 Class I) 2023: 0 inspections (0 OAI), 0 warning letters, 3 recall records (0 Class I) 2024: 0 inspections (0 OAI), 0 warning letters, 9 recall records (1 Class I) 2025: 0 inspections (0 OAI), 0 warning letters, 10 recall records (0 Class I) 2026: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I)
YearInspectionsOAIWarning lettersRecall recordsClass I
202600010
2025000100
202400091
202300030
202220020
202100010
202000071
2019000120
2018000120
201710030

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing AVKARE Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check AVKARE Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Recent recalls

62 recall records from Feb 27, 2015 to Feb 13, 2026. Showing the 20 most recent. View all 62 recall records

NumberClassProductDate
D-0341-2026Class IIAmantadine HCl, Capsules, UPS, 100 mg, 50 Capsules (5 x 10) unit dose, Rx Only, Manufactured for…Feb 13, 2026
D-0292-2026Class IIRosuvastatin Tablets, USP, 10 mg, Rx Only, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured…Dec 31, 2025
D-0007-2026Class IINorgestimate and Ethinyl Estradiol Tablets, USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25…Sep 2, 2025
D-0644-2025Class IIchloroproMAZINE Hydrochloride Tablets, USP, 100 mg, 50 Tablets (5x10) unit dose carton, Rx only…Aug 25, 2025
D-0643-2025Class IIchloroproMAZINE Hydrochloride Tablets, USP, 50 mg, 50 Tablets (5x10) unit dose carton, Rx only…Aug 25, 2025
D-0528-2025Class IIIPitavastatin Tablets, 1 mg, 90 Tablets per bottle, Rx Only, Manufactured for: AvKARE, Pulaski, TN…Jun 26, 2025
D-0529-2025Class IIIPitavastatin Tablets, 2 mg, 90 Tablets per bottle, Rx Only, Manufactured for: AvKARE, Pulaski, TN…Jun 26, 2025
D-0460-2025Class IICelecoxib Capsules, 200 mg, 50 Capsules (5x10) Unit Dose per carton, Rx Only, Manufactured for…May 13, 2025
D-0461-2025Class IIChlorthalidone Tablets, USP, 25 mg, 50 Tablets (5x10) Unit Dose cards per carton, Rx only…May 9, 2025
D-0229-2025Class IISilodosin Capsules, 8mg, 90-count bottle, Rx only, Manufactured for: AvKare, Pulaski, TN 38478…Feb 4, 2025
D-0224-2025Class IIIrbesartan Tablets USP, 300 mg, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE…Jan 21, 2025
D-0176-2025Class IIIPolyvinyl Alcohol Ophthalmic Solution 1.4%, Moisturizing Lubricant Eye Drops, 0.5 FL OZ (15 mL)…Dec 18, 2024
D-0175-2025Class IIICarboxymethylcellulose Sodium Ophthalmic Solution 0.5% Moisturizing Lubricant Eye Drops, 0.5 FL OZ…Dec 18, 2024
D-0168-2025Class IINitrofurantoin Capsules, USP, 100 mg, 50 Capsules (5 x 10) Unit Dose per carton, Rx Only…Dec 4, 2024
D-0110-2025Class IICinacalcet Tablets, 90 mg, 30-count bottle, Rx only, Manufactured for: AvKARE, Pulaski, TN 38478…Nov 27, 2024
D-0108-2025Class IICinacalcet Tablets, 30 mg, 30-count bottle, Rx only, Manufactured for: AvKARE, Pulaski, TN 38478…Nov 27, 2024
D-0109-2025Class IICinacalcet Tablets, 60 mg, 30-count bottle, Rx only, Manufactured for: AvKARE, Pulaski, TN 38478…Nov 27, 2024
D-0104-2025Class IISunitinib Malate Capsules, 25 mg, 28-count bottles, Rx Only, Manufactured for: AvKARE, Pulaski, TN…Oct 18, 2024
D-0103-2025Class IISunitinib Malate Capsules, 12.5 mg, 28-count bottles, Rx Only, Manufactured for: AvKARE, Pulaski, TN…Oct 18, 2024
D-0444-2024Class IAtovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only…Mar 28, 2024

Recent FDA inspections

4 inspections from Jun 9, 2014 to Nov 2, 2022.

DateSiteProductClassificationFEI
Nov 2, 2022Pulaski, TNDrugsVoluntary Action Indicated (VAI)3007255004
Aug 23, 2022Pulaski, TNDrugsNo Action Indicated (NAI)3007255004
Jun 6, 2017Pulaski, TNDrugsNo Action Indicated (NAI)3007255004
Jun 9, 2014Pulaski, TNDrugsNo Action Indicated (NAI)3007255004
NAI
No objectionable conditions or practices were found during the inspection.
VAI
Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI
Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

FDA-inspected facilities

1 inspected site, newest inspection first.

FacilityLocationInspectionsLatest
FEI 3007255004Pulaski, TN4Nov 2, 2022

AVKARE Inc. and the FDA: common questions

Has AVKARE Inc. received an FDA warning letter?

No FDA warning letter addressed to the name "AVKARE Inc." is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.

Has AVKARE Inc. received an FDA Form 483?

FDA has not published a Form 483 for "AVKARE Inc." in its reading room. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect AVKARE Inc.?

The most recent FDA inspection on file ended Nov 2, 2022 at Pulaski, TN and was classified VAI. FDA has 4 inspections of AVKARE Inc. on file.

Has AVKARE Inc. had an FDA recall?

Yes. AVKARE Inc. has 62 FDA recalls on record, 2 of them Class I, the most serious class. The most recent started Feb 13, 2026.

Need more than this page shows? Ask about AVKARE Inc. in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.

Get a free API key

Prefer a PDF? Request a free supplier snapshot.

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.